Background-Chronic pressure overload (such as arterial hypertension) may cause left ventricular (LV) remodeling, alterations in cardiac function, and the development of diastolic heart failure. Changes in the composition of the myocardial extracellular matrix may contribute to the development of pressure-overload-induced LV remodeling. We hypothesized that a specific pattern of plasma biomarker expression that reflected changes in these pathophysiological mechanisms would have diagnostic application to identify (1) patients who have development of LV hypertrophy (LVH) and (2) 
D espite significant advances in diagnosis and management, chronic pressure overload (PO) (such as arterial hypertension) remains one of the most important risk factors for the development of cardiovascular disease and a leading cause of cardiovascular morbidity and mortality. 1, 2 Chronic PO results in significant changes in left ventricular (LV) structure and function, collectively termed myocardial remodeling. [3] [4] [5] [6] This remodeling includes significant changes in myocytes, fibroblasts and the extracellular matrix (ECM), all of which contribute to one of the structural manifestations of PO; the development of LV chamber hypertrophy (LVH). 7 Once established, PO-induced LVH has significant long-term consequences because it serves as a major independent risk factor for the development of chronic heart failure (CHF).
Clinical Perspective on p 256
Although LVH is a pivotal step in the development of PO-induced heart disease, the detection of LVH is made difficult by several factors. First, in and of itself, the clinical disease processes causing PO do not cause symptoms, consequently, LV remodeling may remain an unrecognized and insidious process for a prolonged period of time. Second, LVH is not readily detectable using standard clinical means such as a history, physical examination, or ECG but rather requires costly, specialized testing approaches, and subspecialty expertise to perform and interpret. 8 -13 Therefore, the first goal of this study was to develop a plasma biomarker profile that could be used to identify patients with LVH.
There is a substantial rate of progression from PO-induced LVH to abnormal diastolic function and CHF. Myocardial remodeling, particularly changes in the structure and composition of the ECM, result in abnormal LV filling, a stiff, noncompliant LV, and increased diastolic pressures. A common form of this PO-induced heart failure occurs with a preserved ejection fraction (EF) and is referred to as diastolic heart failure (DHF). 14 -22 However, identification of patients with LVH who have this form of DHF is difficult and requires extensive noninvasive and/or invasive testing and complex algorithmic diagnostic criteria. Therefore, the second goal of this study was to develop a plasma biomarker profile that could be used to identify the patients with DHF.
The plasma biomarkers examined in the current study were those that reflect changes in the underlying mechanisms effecting structural and functional remodeling in PO-induced disease states. One such pathophysiological mechanism is a change in ECM composition, particularly fibrillar collagen. 14, 21, [23] [24] [25] [26] [27] [28] [29] [30] Changes in collagen homeostasis are reflected in measurements or determinants of the rates of collagen synthesis, processing, posttranslational modification, and degradation. [23] [24] [25] [26] [27] [28] [29] [30] We hypothesized that a specific pattern of plasma biomarker expression would have diagnostic application in (1) patients who have LVH and (2) patients with LVH who have DHF. To test these hypotheses, we used highsensitivity assays to examine a large array of plasma proteins and peptides that reflect ECM collagen homeostasis in patients with LVH and DHF.
Methods

Subjects
Four hundred forty-six subjects were enrolled in the present study. There were 241 referent control subjects with no evidence of cardiovascular disease and no evidence of LV structural or functional changes (referent control group). There were 205 subjects with LVH; of these, 144 subjects had LVH but without evidence of heart failure (LVH group) and 61 subjects with LVH and DHF (nϭ61, DHF group).
Subject Recruitment Methods
Study subjects were recruited from locally sponsored health fairs, response to multimedia stories, physician referral, and echocardiographic studies.
Study Protocol
Each subject underwent the following evaluation: a complete medical history, comprehensive physical examination, 12-lead ECG, echocardiogram, 6-minute hall walk, and the plasma biomarkers enumerated below.
Compliance
The research protocol used in this study was reviewed and approved by the institutional review board at the Medical University of South Carolina. Written informed consent was obtained from all participants.
Definitions Used to Define Study Groups
LVH was defined echocardiographically as an increase in LV wall thickness of Ͼ1.2 cm and/or an increase in LV mass index Ն95 in women and Ն115 gm/m 2 in men. 31 DHF was defined using the criteria of the Lahey Clinic and the Heart Failure and Echocardiography Associations of the European Society of Cardiology. [32] [33] [34] Each requires (1) signs or symptoms of heart failure that provide clinical evidence of heart failure (may include Framingham or Boston Criteria, exercise testing, or quality of life questionnaire), (2) preserved EF (Ն50%), (3) normal LV end-diastolic volume index (LVEDVI Ͻ90 mL/m 2 , (4) evidence of diastolic LV dysfunction obtained invasively (using left or right heart catheterization) or noninvasively (using Doppler, tissue Doppler or left atrial measurements), and (5) exclusion of nonmyocardial diseases.
Subjects in the LVH or DHF group were excluded if they had a clinical condition that would potentially change plasma biomarker profiles independent of the presence of LVH or DHF: (1) chronic obstructive pulmonary disease requiring oral steroids and/or oxygen therapy, (2) poorly controlled diabetes, HbA1c Ͼ8.5 within the past 6 months, (3) cardiac surgery, electrophysiological ablation, or percutaneous coronary intervention within the past year, (4) major surgical procedures (defined as requiring a hospital stay of Ͼ3 days) in the past 6 months, (5) ST-segment elevation myocardial infarction, or non-ST-segment elevation myocardial infarction (by history, ECG, or review of patient record), or a wall motion abnormality by echocardiography, (6) end-stage renal disease, creatinine Ͼ2.0 mg/ dL, (7) active or ongoing malignancy, (8) severe rheumatological disease (ie, scleroderma, lupus, or sarcoidosis), (9) an EF of Ͻ50% or an LVEDV Ͼ90 mL/m 2 , (10) valve disease more extensive than mild, (11) severe liver disease, (12) amyloidosis, hypertrophic cardiomyopathy, restrictive or constrictive cardiomyopathy, HIV, (13) significant medication changes within the previous 4 weeks, (14) significant anemia with hemoglobin Ͻ10.5 g, (15) active or ongoing severe infection, or (16) age Ͻ50 years.
Referent control subject were excluded if (1) any exclusion listed for the LVH and DHF groups were present, (2) there was abnormal LV function, volume, or mass as assessed by echocardiography, or (3) age was Ͻ50 years.
Echocardiographic Methods
All echocardiograms were performed by an experienced sonographer (C.D.M.), using a Sonos 5500 system (Agilent Technologies, Andover, MA) with an S4 2-to 4-MHz ultrasound transducer. Measurements were made using American Society of Echocardiography criteria. 31, 34 EF was calculated using the standard formula. LV mass was calculated using the formula of Reichek and Devereux. 35 Volume and mass were indexed for body surface area. Doppler measurements of mitral inflow E-wave velocity, A-wave velocity, the E/A ratio. Tissue Doppler measurements of mitral EЈ and AЈ wave velocity were made. Pulmonary capillary wedge pressure (PCWP) was calculated using the formula 2ϩ1/3 E/EЈ. 23, 36 An average of 3 beats was used for every measurement. Images were coded and read in a blinded fashion by at least 2 of 3 authors (S.M.M., M.R.Z., C.D.M.). 14, 15, 24, 25, 28, 29, [37] [38] [39] Four classes of MMPs: gelatinases (MMP-2 and MMP-9), collagenase (MMP-1 and 8), stromelysin (MMP-3), and matrilysin (MMP-7) and all 4 tissue inhibitors of MMPs (TIMP-1, -2, -3, -4) were examined. 23, 26, 40 Blood was collected after the subject had remained supine for 20 minutes. Samples were immediately centrifuged and the plasma layer removed. The separated plasma was divided into 3 equal aliquots and frozen at Ϫ70°C. Samples were not thawed and refrozen. For measurement, the plasma samples were thawed on ice.
Plasma Biomarker Measurements
All measurements were performed in duplicate. For the MMP and TIMP assays, a multiplex suspension array approach was used. For PINP and PIIINP, a radioimmunoassay was used. For the remaining plasma proteins, enzyme-linked immunoassays were used. For the MMP and TIMP measurements, the plasma was first diluted 1:100, incubated with either the MMP platform (MMP Base Kit LMP000) or the TIMP platform (TIMP MSA kit, LKT003), and the samples were then subjected to 2-laser flow cytometric detection system (Bio-Plex 200, BioRad Laboratories). Using precalibrated standards and regression modeling, the fluorescence emission specific to each MMP and TIMP type was converted to an absolute concentration. For the PINIP and PIIINP assays, the plasma was diluted 1:2, incubated with I 125 -labeled targeted antisera, specifically bound conjugates separated by differential centrifugation, and scintillation counting performed (Wallac 1480 Wizard, Waltham, MA). The final plasma concentrations were calculated from a competitive semilog calibration curve. To measure plasma cardiotrophin, osteopontin, and sRAGE levels, a sandwich enzyme-linked immunoassay was performed. In general terms, plasma was added to a 96-well plate containing the targeted antisera, after rigorous washing steps and conjugation with a secondary detection antisera, and the resultant colorimetric reaction was read by scanning spectrophotometry (VersaMax, Molecular Devices, Sunnyvale, CA). For the CITP measurements, a competitive immunoassay was performed and the resultant reaction was analyzed by scanning spectrophotometry. The specific concentrations of the plasma proteins in each sample were then determined by comparison to a standard curve generated from known concentrations of each plasma protein. The NT-proBNP assay was performed using VITROS Products NT-proBNP Reagent Pack and Calibrators on the VITROS ECi/ECiQ Immunodiagnostic System (Ortho-Clinical Diagnostics). The assay uses an immunometric technique in which the NT-proBNP present in 40 L of EDTAplasma specimen reacts simultaneously with a biotinylated antibody (sheep anti-NT-proBNP) and a horseradish peroxidase-labeled conjugate (sheep anti-NT-proBNP). The sensitivity for all of the assays was in picrograms per milliliter, with intra-assay coefficient of variation Ͻ15%.
Statistical Analysis
Statistical analyses were performed with SAS (version 9.2; SAS Institute, Inc, Cary, NC). The distribution of measurements derived from demographic variables, echocardiograms, and plasma biomarkers were tested for normality based on tests of skewness and kurtosis.
Demographics and Group Differences
Comparisons were made among 3 groups: referent control, LVH, and DHF, using an ANOVA F test. All pairwise comparisons were adjusted for multiple comparisons using the Tukey and Kramer methods. Values are presented as meanϮSEM as well as medians and interquartile ranges (online-only Data Supplement Table A) . Because of right skewness, for analytic purposes, biomarker values were log base 10 transformed. A probability value Ͻ0.05 was considered significant. In Tables 1 and 2 , referent control subjects (nϭ241) were compared with patients with LVH but no DHF (nϭ166) and patients with LVH and DHF (nϭ61). LVH indicates patients with left ventricular (LV) hypertrophy but no heart failure; DHF, patients with LV hypertrophy and diastolic heart failure; E and A, pulsed-wave Doppler mitral valve E-and A-wave inflow velocities; EЈ, tissue Doppler (lateral mitral annulus) EЈ velocity; PCWP, pulmonary capillary wedge pressure calculated from the formula 2ϩ1.3 (E/EЈ); EDV, end-diastolic volume; and EDD, end-diastolic dimension.
Data are meanϮSEM. All continuous data are compared using ANOVA F test. All categorical data are compared using 2 test statistic. *PϽ0.05 compared with referent control. †PϽ0.05 compared with LVH.
Predictive Modeling
In Tables 3 and 4 , univariable and multivariable analyses were performed: (1) comparing all patients with LVH (nϭ205) with referent control subjects (nϭ241) and (2) comparing patients with LVH but no DHF (nϭ144) with patients with LVH and DHF (nϭ61). Multiple logistic regression was used to analyze binary indicators of LVH and DHF. To determine relevant predictors of these outcomes, plasma biomarkers were first assessed for univariable associations with clinical outcomes. An area under the curve (AUC) analysis was performed on each individual biomarker with a probability value Ͻ0.15 for association with LVH or DHF. Those biomarkers with a Wald PϽ0.15 were considered for inclusion in a multiple logistic regression model. Using forward stepwise variable selection, biomarkers were added to the model. In forward stepwise variable selection, the variable most strongly associated with outcome (with respect to statistical significance) was added to the model, and this process was continued until no more variables meet the entry criterion of ␣ϭ0.10. The ␣ was set at 0.10 to ensure that even marginally predictive biomarkers were captured. The univariable and multivariable logistic regression models were adjusted for the following clinical covariates: systolic blood pressure, diastolic blood pressure, age quartile, sex, and body mass index. Quadratic and cubic age terms were assessed, but, ultimately, age quartile was determined to be the most relevant predictor. ␤ Values and probability values for each biomarker are presented for the adjusted models (online-only Data Supplement Table) . The effects of antihypertensive medications were analyzed by drug class: angiotensinconverting enzyme inhibitor-I or angiotensin receptor blocker, ␤-blockers, calcium channel blockers, and diuretics. None of these medications were significantly associated with any of the biomarkers used in the final multivariable analyses for LVH or DHF patients.
Cross-Validation
The discriminative value of the models for LVH and DHF was assessed by calculating the AUC (Figures 1 and 2) . The model AUC was estimated using 5-fold cross-validation across 30 simulated splits of the data. For this procedure, the data were divided into approximately 5 equal parts, and the model was fitted to 80% of the data. The AUC was then calculated, based on validating the model on the remaining 20% of the data. This was repeated for all 5 splits of the data, leaving 1 split out each time for the purpose of validation. The procedure was conducted 30 times for simulated data splits, and an average cross-validated AUC was reported. This data simulation methodology for validating a predictive model avoids biasing the study toward a higher AUC that one would obtain if the model was validated on the same data originally used to derive the model. In addition, observation of the simulated AUC curves allows researchers to determine whether any parts of the curve are unstable. Finally, the cross-validated AUC for LVH and DHF were compared with that resulting from a logistic regression model with clinical covariates alone, and with clinical covariates plus NT-proBNP. Results are reported as AUC or cross-validated AUC [95% CI].
A test of calibration and goodness of fit as suggested by the Hlatky et al 41 in the American Heart Association statement on biomarkers was performed. Predicted risk based on the clinical covariates plus 5 biomarker panels and clinical covariates plus 4 biomarker panels, for LVH and DHF, respectively, were grouped into deciles. The predicted versus the observed proportion (risk) of events were plotted at each decile (Figure 3) , and finally, Hosmer Lemeshow 2 goodnessof-fit tests were conducted.
Results
Patient Demographics and Echocardiography
Demographics and LV echocardiographic data are presented in Table 1 . In the LVH group, body surface area and blood pressure were increased compared with referent control values. In the DHF group, body surface area and blood pressure were increased compared with the referent control subjects, and the DHF subjects were older and had a diminished 6-minute hall walk compared with both the control and LVH groups. Whereas blood pressure values were elevated in both the LVH and DHF groups, these values remained within the therapeutic range suggested by JNC IV guidelines. 1 There were no significant differences between referent control, LVH, and DHF subjects with respect to LVEDV or EF. Consistent with the criteria for LVH, LVED wall thickness and mass were increased in both the LVH and DHF groups compared with referent control subjects. In the DHF group, E/EЈ and PCWP were increased compared with the LVH and referent controls.
Plasma Biomarkers
The absolute values for all of the plasma biomarkers measured in the 3 groups of subjects are shown in Table 2 . Compared with referent control values, plasma MMP-9, TIMP-1, TIMP-2, and osteopontin were increased in the LVH group; the other biomarkers (including MMP-1) were not significantly different. In the DHF group, MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, TIMP-2, TIMP-4, PIINP, CITP, osteopontin, and NT-proBNP were increased compared with referent control values, whereas MMP-8 values were reduced and the other biomarkers (including MMP-1) were not significantly different. These plasma analytes were next considered as univariable predictors of LVH and/or DHF before and after adjustment for clinical variables; the results from this analysis are presented in Table 3 and in online-only Data Supplement Tables B and C.
Multivariable Predictors
One of the major objectives of this study was to develop a multivariable model of plasma biomarkers that would discriminate the presence of LVH as well as for DHF. Accordingly, a number of forward modeling and cross-validation iterations were performed both unadjusted (online-only Data Supplement Table B ) and adjusted for clinical variables (Table 4) . For LVH, the best predictive fit was obtained when a total of 5 biomarkers were used in the model. For DHF, the best fit from forward variable selection was achieved when 4 biomarkers were used in the model. In light of the fact that plasma profiles of NT-proBNP have been considered a benchmark as a biomarker for CHF, 10, 15, 42 these models were compared with the AUC for NT-proBNP alone.
Left Ventricular Hypertrophy
The AUCs resulting from 1, 2, 3, 4, and 5 biomarkers panels are presented in online-only Data Supplement Table A. The best-fit model was achieved using 5 biomarkers consisting of NT-proBNP, MMP-7, MMP-9, TIMP-1, and PIIINP. This regression model adjusted for systolic blood pressure, diastolic blood pressure, age quartile, sex, and body mass index is presented in Table 4 . The receiver operator curve for this 5-biomarker model is shown in Figure 1A Figure 1B) . The sensitivity and specificity at the "shoulder" LVH indicates patients with left ventricular (LV) hypertrophy but no heart failure; DHF, patients with LV hypertrophy and diastolic heart failure; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of MMP; NT-proBNP, N-terminal propeptides of brain natriuretic peptide; sRAGE, soluble receptor for advanced glycation end product; PINP, N-terminal collagen I propeptide; PIIINP, N-terminal collagen III propeptide; CITP, collagen I telopeptide; AUC, area under the curve, adjusted AUC values (with 95% confidence intervals), and P value indicate the model was adjusted for clinical covariates: systolic blood pressure, diastolic blood pressure, age quartile, sex, and body mass index. For LVH, analyses were performed comparing all patients with LVH (nϭ205) with referent control subjects (nϭ241). For DHF, analyses were performed comparing patients with LVH but no DHF (nϭ144) with patients with LVH and DHF (nϭ61). For LVH, the AUC using the clinical covariates alone was 0.73 ͓0.69 -0.78͔. For DHF, the AUC using the clinical covariates alone was 0.68 ͓0.60 -0.76͔. of the receiver operating characteristic (ROC) curves where the sum of sensitivity and specificity was the highest was examined. For LVH, to detect 80% of true positives based on these biomarkers (sensitivity), there will be a 45% falsepositive (1-specificity) rate. The calibration of the risk predictors was made by comparing the predicted versus observed frequency of events. The resultant analysis showed that the average observed risk versus predicted risk calculated within deciles of predicted risk followed a linear pattern for LVH (Figure 3 ). These results along with an insignificant HosmerLemeshow goodness of fit statistic ( 2 ϭ4.68, Pϭ0.79) confirm a high degree of goodness of fit of the model.
Diastolic Heart Failure
The AUCs resulting from 1, 2, 3, and 4 biomarkers are presented in online-only Data Supplement Table A. The best-fit model was achieved using 4 biomarkers consisting of MMP-2, MMP-8, TIMP-4, and PIIINP. This regression model adjusted for systolic blood pressure, diastolic blood pressure, age quartile, sex, and body mass index is presented in Table 4 . The ROC for this 4-biomarker model is shown in Figure 2A Figure 1B ). The highest sensitivity and specificity at the "shoulder" of the ROC curves was 
LVH indicates patients with left ventricular (LV) hypertrophy; DHF, patients with LV hypertrophy and diastolic heart failure; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of MMP; NT-proBNP, N-terminal propeptides of brain natriuretic peptide; PIIINP, N-terminal collagen III propeptide; AUC, area under the curve (with 95% confidence intervals); and CV, cross-validated.
All models were adjusted for systolic blood pressure, diastolic blood pressure, age quartile, sex, and body mass index. For LVH, analyses were performed comparing all patients with LVH (nϭ205) with referent control subjects (nϭ241). For DHF, analyses were performed comparing patients with LVH but no DHF (nϭ144) with patients with LVH and DHF (nϭ61). examined for DHF: To detect 80% of true-positives based on these biomarkers, there will be a 40% false-positive rate. The resultant analysis showed that the average observed versus predicted risk calculated within deciles of predicted risk followed a linear pattern for DHF (Figure 3 ). These results along with an insignificant HosmerLemeshow goodness-of-fit statistic ( 2 ϭ3.63, Pϭ0.89) confirm a high degree of goodness of fit of the model. Therefore, the use of a multibiomarker panel improved detection of LVH and DHF compared with clinical covariates alone, NT-proBNP alone, or any single biomarker.
Discussion
The development of LVH is an important risk factor for the progression to DHF. Both LVH and DHF have been associated with an increase in cardiovascular morbidity and mortality. 5,6,16 -22,43 However, a simple and specific analytic approach to detect the presence of LVH, and, more importantly the progression to DHF in an ambulatory/outpatient context, remains elusive. We hypothesized that specific multibiomarker panels measured in the plasma could be used to identify patients with LVH and DHF. Generically, biomarkers consist of peptides, proteins, and enzymes, which reflect the presence and status of an underlying pathophysiological condition. 24 -26,38 -40,42 Biomarkers are well accepted analytic adjunctive tools in the context of hematologic, infectious, neoplastic, and metabolic disease. However, the use of biomarkers to identify the presence of LVH and the progression to DHF have only recently been considered, and most studies examined only a single biomarker in their analysis. 14, 15, 25, 38, 39, 42, 44, 45 The goal of this project was to test the discriminative value of a large portfolio of candidate biomarkers in patients with LVH and/or DHF, which were relevant to their underlying pathophysiology. These candidate biomarkers were focused on myocardial ECM remodeling pathways because ECM remodeling is a common event in the development of LVH and progression to DHF. 14,20 -26 In addition, these candidate biomarkers were compared with values obtained from a reference, univariable biomarker that has been used in previous CHF studies, NT-proBNP. 15, 42 The unique, important findings in this study were 2-fold. First, a specific panel of biomarkers, reflective of the matrix remodeling process, could be used in predictive modeling algorithms for both LVH and DHF. Specifically, a multibiomarker panel that included MMP-7, MMP-9, TIMP-1, PIIINP, and NT-proBNP provided a prediction algorithm for LVH (AUCϭ0.80) and a multibiomarker panel that included MMP-2, MMP-8, TIMP-4, and PIIINP provided a prediction algorithm for DHF both with good sensitivity and acceptable specificity (AUCϭ0.79). Second, the multibiomarkers panels for LVH and DHF provided better predictive models than when each biomarker was considered as a single entity, better than using clinical covariates alone, and better than measuring NT-proBNP alone. Although these biomarker panels require more rigorous study in a larger, more diverse patient population, these findings demonstrate the proof-of-concept that a multibiomarker panel measured from a peripheral blood sample holds promise as a diagnostic tool to identify the presence of LVH and DHF.
Biomarkers of ECM Homeostasis
Recently published guidelines for the development of biomarkers have emphasized the importance of the link between underlying pathophysiology and the predictive capabilities of the biomarkers chosen. Accordingly, biomarkers of ECM homeostasis were selected for this study because past studies demonstrated that the adaptive response to PO includes structural and biochemical "remodeling" of both cellular and extracellular compartments. 14,20 -26 Both collagen type I and III must undergo a series of sequential postsynthetic processing steps in order to become a mature structural collagen fibril. One of these steps is cleavage of the N-terminal propeptide of procollagen I and III (PINP, PIIINP, respectively). When collagen is degraded, 1 proteolytic fragment is CITP. Both the propeptides and telopeptides are of small molecular weight and thereby move from the interstitial space into the vascular compartment, which in turn allows for quantification in a systemic blood sample. 14, 24, 25 In the present study, univariable analysis demonstrated that PIIINP was increased in patients with LVH and DHF; CITP was increased in DHF patients. Thus, consistent with past reports, PO was associated with increased indices of collagen synthesis and degradation indicative of accelerated ECM turnover. 14,24 -26 Importantly, however, the present study built on these observations using multivariable modeling to demonstrate that PIIINP but not CITP was an important variable in the predictive model for LVH as well as DHF. This result emphasizes the concept that the use of a single measurement or a univariable approach in a dynamic, diverse, and complex structure such as the myocardial ECM may be insufficient to assess the utility of biomarkers for the detection and prediction of LVH and/or DHF.
One of the determinants effecting ECM degradation is the induction and activation of a large family of zinc-dependent interstitial proteases, the MMPs. In general terms, the classification of MMPs is based on substrate affinity and specificity. The present study measured plasma levels of MMPs from each of the soluble classes: the collagenases (MMP-1,-8), gelatinases (MMP-2,-9), and stomelysins/matrilysins (MMP-3,-7). 26 A systematic approach to measuring a full profile of MMPs and performing multivariable predictive analysis had not been previously performed. Recent community based studies demonstrated an approximately 2-fold increased risk of hypertension progression in subjects with elevated MMP-9 levels. 46 -49 Moreover, these elevated MMP-9 plasma levels were associated with higher PIIINP levels. In the present study, both PIIINP and MMP-9 were important components of the multibiomarker prediction modeling for LVH. Taken together, previous and present studies suggest that PIIINP and MMP-9 are important biomarkers for identifying patients at high risk for LVH and adverse ECM remodeling.
The present study demonstrated that a different plasma MMP profile emerged for DHF patients compared with LVH patients. Specifically, plasma MMP-2 and MMP-7 were increased, whereas MMP-8 levels were decreased. This probably reflects a local shift in cell type activation as well as ECM proteolytic events occurring in DHF patients. Specifically, increased plasma MMP-2 levels would imply a more generalized proteolytic state, which in turn would heighten ECM instability and turnover. 26, 46 On the other hand, increased MMP-7 levels have been associated with the woundhealing response, are expressed in resident cells such as macrophages, and may be indicative of local alterations in the cell types and expression patterns occurring within the ECM. 26 In addition, the decrease in MMP-8 in the DHF patients suggests a phenotypic change in cell types and MMP expression patterns. MMP-8, a neutrophil collagenase, may be reflective of changes in neutrophil synthesis and activation.
One of the critical control points for MMP proteolytic activity is the expression and binding of endogenous tissue inhibitors of MMPs (TIMPs). TIMPs bind to the activated MMP or proMMP, thus regulating MMP activity in vivo. 26,50 -52 In addition, TIMPs may be potent fibroblast growth factors and stimulate profibrotic signaling cascades. 26,50 -52 All of 4 known TIMPs are expressed within the human myocardium, with TIMP-4 having a predominantly cardiovascular expression. 26, 51 The present study is the first to comprehensively measure all 4 TIMPs within the plasma of a large cohort of referent control and LVH and DHF subjects. Consistent with past reports, plasma TIMP-1 levels were increased in LVH patients. 23, 53 In patients with DHF, TIMP-4 levels were increased compared with both referent control and LVH subjects and would imply a further induction of a myocardial profibrotic state.
Diagnostic Utility of Plasma Biomarkers and Current Diagnostic Strategies
Epidemiological studies have identified clinical and demographic factors that increase the risk of developing LVH; these include increased age, female sex, obesity, and uncontrolled blood pressure. 8 -20 However, knowledge of these risk factors alone cannot provide the means to predict the presence of LVH, hold no real specificity and sensitivity for predicting LVH, and are not useful in a clinically relevant context. As such, analytic measurements that would be easy to use and be cost-effective for the detection of LVH in an ambulatory setting would have significant clinical import. Unfortunately, outside of advanced imaging methodologies, the diagnosis of LVH cannot currently be made with sufficient accuracy. For example, ECG methods, even when rigorously applied, can provide 70% specificity but Ͻ30% sensitivity. 12, 13 Therefore, to date, the determination of LVH requires noninvasive imaging using an echocardiogram, MRI, or multislice computed tomography. The present study demonstrated that a 5-analyte biomarker panel could be developed to predict the presence of LVH. The sensitivity and specificity of this plasma multibiomarker profile exceeded that of any single biomarker (including NT-proBNP) and exceeds any currently available screening algorithm (eg, clinical examination, ECG) for LVH.
A number of criteria have been proposed for the diagnosis of DHF, including symptoms and signs of heart failure, a preserved EF, a normal LVEDV, clear evidence of abnormal diastolic function, and no evidence of nonmyocardial disease. [32] [33] [34] These were the criteria used in the current study to make the diagnosis of DHF. There are, however, a number of limitations to these diagnostic criteria. For example, the symptoms and signs of heart failure may be nonspecific and may be caused by factors other than heart failure. Detecting abnormalities in diastolic function, measuring EF and LV volume require noninvasive imaging such as an echocardiogram or MRI, which are costly and require subspecialty expertise to perform and interpret. In addition, many indices of diastolic function become abnormal with what may be considered normal aging. Thus, there are no available adjunctive analytic tests that can be applied in the ambulatory care setting to identify the presence of DHF. The ability to use a plasma profile to screen, diagnose, and follow patients with DHF would provide a significant clinical advancement.
The most advanced use of a single biomarker in the context of CHF is that of the natriuretic peptides, which include NT-proBNP. 10, 15, 42 However, the sensitivity and specificity of natriuretic peptide levels such as NT-proBNP are significantly affected by comorbidities and other demographic factors. 10, 15, 42 These confounding factors include age, obesity, sex, and renal, pulmonary, and liver dysfunction. 42, 54 Nevertheless, NT-proBNP has become an accepted biomarker to provide additional supportive evidence for the presence of systolic heart failure. 42 However, whether and to what degree NT-proBNP may be useful in patients with DHF, particularly in ambulatory patients with compensated stable DHF, remains unclear. 20, 21 Accordingly, the present study evaluated plasma NT-proBNP within the multivariable model and the univariable model for comparative purposes. In the multivariable models, NT-proBNP was 1 of the 5 final variables that provided the highest AUC value for LVH. Interestingly, in patients with DHF, NT-proBNP was not useful in the multivariable predictive model, in which the final multivariable biomarker model (MMP-2, MMP-8, TIMP-4, and PIIINP) provided a sensitivity and specificity, which was approximately 20% higher than NT-proBNP alone.
Limitations, Future Directions, and Conclusion
Recent reviews and an American Heart Association scientific statement emphasized the importance for developing biomarkers to enhance diagnostic methods and provide surrogate measures of treatment efficacy. 41, 42, 55, 56 Some of these considerations have been successfully addressed in the present study, whereas others have not. For example, it has been suggested that biomarkers should reflect the underlying pathophysiological mechanisms responsible for outcomes examined. 42, 55, 56 The biomarkers measured in the present study fulfill this requirement. In addition, it is clear that no single biomarker is optimal for screening, diagnosis, and potentially disease management, and therefore the multivariable modeling used in the present study addressed this issue. 23, 38, 40, 42, [47] [48] [49] 55, 56 Finally, the current study clearly fulfilled the recommended first "phase of evaluation" outlined by the American Heart Association. However, as such, the outcomes from the current study represent an initial proof of concept and must be evaluated in a more rigorous fashion before they can become a clinically viable analytic test. Prospective validation, clinical utility, clinical outcomes, and cost-effectiveness are necessary next steps in the evaluation of the biomarkers proposed herein. The methods used to recruit the study patients did not result in a completely random sample but selected a group with disproportionate representation of women and blacks and patients with obesity, hypertension, and LVH. Therefore, it was not possible to control for demographic distribution or test for incremental value over and above the risk presented by the demographic characteristics of the study population. The additional phases of evaluation will now be possible to pursue because the current study has provided a robust proof of concept.
The current study was designed and conducted to provide a proof-of-concept analysis that would then lead to further large, pivotal, definitive studies. Accordingly, a conservative approach of cross-validation in each step (including for variable selection) was used so that any variables that were marginally associated with outcome would not be missed and could be more definitively examined in future studies. It is possible that different splits of the data would result in retention of different covariates if a uniformly cross-validated approach had been taken; however, it is unlikely that this outcome would have occurred because there were no additional biomarkers for LVH or DHF that came close to the 0.10 ␣ level when added to the final adjusted models. Therefore, the current study provides the proof-of-concept necessary to conduct a large, pivotal, definitive study.
Furthermore, in the current study, patients with significant comorbidities were excluded. These circumstances avoided the effects of transient changes in biomarkers associated with acute decompensation and avoided the possibility that other disease process may confound these results. Nevertheless, the present study provides a clinical proof of concept that a multibiomarker panel has discriminative value in identifying the presence of structural and clinical manifestations of PO-induced heart disease. 
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